Identification of a novel crizotinib-sensitive BCL11A-ALK gene fusion in a nonsmall cell lung cancer patient

Abstract excerpt

Until now, more than 10 different ALK fusion partners have been discovered in nonsmall cell lung cancer (NSCLC): EML4, KIF5B, KLC1, TFG, TPR, HIP1, STRN, DCTN1, SQSTM1 and BIRC 6, among others [1, 2]. We report here a novel ALK fusion partner in a NSCLC patient who responded well to the ALK inhibitor crizotinib. We report a novel ALK fusion partner in a NSCLC patient who responded well to the ALK inhibitor crizotinib

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Lung Cancer Research Studies
• Share to Lung Cancer Treatments and Mutations
• Share to Pancreatic and Hepatic Oncology Research